Attached files
file | filename |
---|---|
EX-99.1 - EXHIBIT 99.1 - ONLINE DISRUPTIVE TECHNOLOGIES, INC. | exhibit99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) April 29, 2014
ONLINE DISRUPTIVE TECHNOLOGIES,
INC.
(Exact name of registrant as specified in its
charter)
Nevada | 000-54394 | 27-1404923 |
(State or other jurisdiction | (Commission File | (IRS Employer |
of incorporation) | Number) | Identification No.) |
3120 S. Durango Dr. Suite 305, Las Vegas, Nevada
89117
(Address of principal executive offices and Zip Code)
Registrant's telephone number, including area code: (702) 579-7900
Not Applicable
(Former name or former
address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a -12)
[ ] Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d
-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e -4(c))
2
Item 8.01 Other Events.
Our majority owned Israeli subsidiary, Savicell Diagnostic Ltd., has received approval of the Ethics Committee of the Institutional Review Board of the Carmel Medical Center in Haifa to perform clinical trials on human blood for Savicells blood test for early diagnosis of Lung cancer.
In addition, Savicell has received approval of the Ethics Committee of the Institutional Review Board of the Shaare Zedek Medical Center in Jerusalem to perform clinical trials on human blood for Savicells blood test for early diagnosis of breast cancer. Shaare Zedek is now an additional clinical trials site to Tel Aviv Sourasky Medical Center for early diagnosis of breast cancer.
The Savicell platform is a blood test inherently designed for the early detection of disease. In contrast to existing technologies that evaluate secretions of cancer cells, Savicell gets data directly from the immune system. Disease intrusion and cell malformation, including cancer, are first detected in the body by the immune system, which is energized to rid the body of the malignancy. The initial immune response is intricate, deploying different metabolic pathways and subtypes of cells. The Well-Shield technology is designed to detect and interpret these differential metabolic responses.
This unique technology is inherently designed to be deployed for cancer, autoimmune diseases like multiple sclerosis, and infectious diseases like viral and bacterial pathogens. Initially Savicell is focused on the multibillion dollar cancer diagnosis market. Past clinical results indicate the capacity to distinguish healthy individuals from cancer patients. Savicell is progressing with clinical work for a test specific to breast cancer. Savicellhas realized encouraging early reviews of its breast cancer readout albeit on a relatively small sample size. The addition of an approved breast cancer clinical site is expected to speed up sample acquisition.
Savicell commenced clinical trials of lung cancer test during the month of April, 2014.
Item 9.01 Financial Statements and Exhibits
99.1 | news release dated April 29, 2014 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ONLINE DISRUPTIVE TECHNOLOGIES, INC.
By: | /s/ Giora Davidovits | |
Giora Davidovits | ||
President, Chief Executive Officer, Secretary, | ||
Treasurer and Chief Financial Officer |
Dated: April 29, 2014